A
594.65
-5.22 (-0.87%)
| Previous Close | 599.87 |
| Open | 599.87 |
| Volume | 224,496 |
| Avg. Volume (3M) | 341,419 |
| Market Cap | 36,309,094,400 |
| Price / Earnings (TTM) | 46.53 |
| Price / Earnings (Forward) | 86.21 |
| Price / Sales | 17.74 |
| Price / Book | 6.62 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | 37.05% |
| Operating Margin (TTM) | 13.41% |
| Diluted EPS (TTM) | 12.76 |
| Quarterly Revenue Growth (YOY) | 81.30% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | argenx SE | Bullish | Bullish |
AIStockmoo Score
2.0
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 3.0 |
| Average | 2.00 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 56.92% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,100.00 (Guggenheim, 84.98%) | Buy |
| Median | 717.50 (20.66%) | |
| Low | 680.00 (Baird, 14.35%) | Hold |
| Average | 769.63 (29.43%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 603.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 17 Apr 2025 | 796.00 (33.86%) | Buy | 596.20 |
| Wedbush | 16 Apr 2025 | 715.00 (20.24%) | Buy | 587.59 |
| 11 Apr 2025 | 715.00 (20.24%) | Buy | 580.94 | |
| HC Wainwright & Co. | 11 Apr 2025 | 720.00 (21.08%) | Buy | 580.94 |
| 08 Apr 2025 | 720.00 (21.08%) | Buy | 548.93 | |
| Guggenheim | 10 Mar 2025 | 1,100.00 (84.98%) | Buy | 571.00 |
| Baird | 04 Mar 2025 | 680.00 (14.35%) | Hold | 621.25 |
| Citizens Capital Markets | 28 Feb 2025 | 701.00 (17.88%) | Buy | 624.67 |
| Oppenheimer | 28 Feb 2025 | 704.00 (18.39%) | Buy | 624.67 |
| Wells Fargo | 28 Feb 2025 | 741.00 (24.61%) | Buy | 624.67 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |